GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » EBITDA Margin %

PolyPeptide Group AG (XSWX:PPGN) EBITDA Margin % : -1.48% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PolyPeptide Group AG's EBITDA for the six months ended in Dec. 2023 was CHF-2.6 Mil. PolyPeptide Group AG's Revenue for the six months ended in Dec. 2023 was CHF177.8 Mil. Therefore, PolyPeptide Group AG's EBITDA margin for the quarter that ended in Dec. 2023 was -1.48%.


PolyPeptide Group AG EBITDA Margin % Historical Data

The historical data trend for PolyPeptide Group AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG EBITDA Margin % Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial 24.32 26.25 29.55 12.71 -6.91

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.57 19.98 6.12 -14.69 -1.48

Competitive Comparison of PolyPeptide Group AG's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's EBITDA Margin % falls into.



PolyPeptide Group AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PolyPeptide Group AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-20.89/302.135
=-6.91 %

PolyPeptide Group AG's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.626/177.806
=-1.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (XSWX:PPGN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


PolyPeptide Group AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines